NCT03976245
Advanced Therapeutics in Rheumatoid Arthritis (RA)
Recruiting · Phase 4 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · registry updated 2024-11-29
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
Inclusion
- patients with RA who meet criteria for obtaining an advanced therapeutic through usual care
- active RA with 5 or more swollen joints
- seropositive
- presence of erosions
- failure of methotrexate and hydroxychloroquine and sulfasalazine
- failure of Leflunomide
Exclusion
- no contraindication to etanercept or tofacitinib
- active serious infection
- active Tuberculosis
- multiple sclerosis
- current cancer
- lymphoma ever